This clinical trial is focused on studying the effects of certain medications on people with atherosclerotic cardiovascular disease, a condition where the arteries become narrowed and hardened due to a buildup of cholesterol and other substances. The study aims to compare the effectiveness of two treatments, Inclisiran and bempedoic acid, in lowering levels of LDL cholesterol, often referred to as “bad” cholesterol, which can contribute to heart disease. Participants in the study will receive either Inclisiran, which is given as an injection, or bempedoic acid, which is taken as a tablet. Both treatments will be used alongside standard care, which may include medications like atorvastatin, rosuvastatin, and ezetimibe.
The purpose of the study is to determine if Inclisiran is more effective than bempedoic acid in reducing LDL cholesterol levels over a period of 150 days. Participants will be randomly assigned to receive one of the treatments and will be monitored throughout the study to assess changes in their cholesterol levels. The study will also look at how well participants respond to the treatments, aiming for LDL cholesterol levels to reach specific targets based on their risk of heart disease.
Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study is designed to provide valuable information on how these medications can help manage cholesterol levels in people with atherosclerotic cardiovascular disease, potentially leading to better treatment options in the future. A placebo may be used in some cases to compare the effects of the active treatments. The study is expected to conclude in 2025.



Germany